New AI Tech To Improve AFib Treatment Slated For 2020 Market Launch
Executive Summary
Marseille-based Volta Medical is targeting a 2020 release for its AI software to guide cardiologists through atrial fibrillation (AF) procedures. The start-up has recently published data demonstrating the potential of its technology.
You may also be interested in...
Cardio Conversations: 'Trials, Trials, Trials!' Volta Has Big Ambitions For AI In EP
In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical, a Marseille-based company applying artificial intelligence to electrophysiology. Volta has raised over €70m and is sponsoring the TAILORED AF trial to show that its software can make atrial fibrillation ablation more effective.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.